COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00359450
Recruitment Status : Terminated
First Posted : August 2, 2006
Last Update Posted : March 2, 2010
Information provided by:
Bristol-Myers Squibb

Brief Summary:

BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled:

  • Cohort I: Patients previously treated with one taxane containing regimen.
  • Cohort II: Patients previously treated with a platinum based but non-taxane containing regimen.
  • Cohort III: Patients previously treated with both a chemotherapy regimen and one EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) compound.

Patients in cohorts I and II should have not been treated with a prior EGFR-TKI compound. Prior treatment with a VEGFR (vascular endothelial growth factor receptor) inhibitor compound is allowed for all the patients provided that the VEGFR inhibitor is not also an EGFR inhibitor.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: BMS-275183 (oral taxane) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 186 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients
Study Start Date : July 2006
Actual Primary Completion Date : March 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. To assess efficacy of BMS-275183 in pretreated NSCLC patients as measured by the tumor response rate

Secondary Outcome Measures :
  1. To further characterize the qualitative and quantitative toxicities of BMS-275183 in the same patient population
  2. Assess the response duration
  3. Assess the progression free survival time
  4. Assess the overall survival time
  5. Assess the pharmacokinetics (PK) of BMS-275183

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women, age >= 18 years
  • Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC who failed only one prior chemotherapy regimen.

Exclusion Criteria:

  • Concomitant medication with a cytochrome P450 (CYP) 3A4 inhibitor or inducer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00359450

Layout table for location information
United States, Massachusetts
Local Institution
Burlington, Massachusetts, United States
United States, Missouri
Local Institution
St. Louis, Missouri, United States
United States, North Carolina
Local Institution
Morganton, North Carolina, United States
United States, Ohio
Local Institution
Cleveland, Ohio, United States
Local Institution
Charleroi, Belgium
Local Institution
Leuven, Belgium
Canada, Ontario
Local Institution
Montreal, Ontario, Canada
Local Institution
Thunder Bay, Ontario, Canada
Local Institution
Toronto, Ontario, Canada
Canada, Quebec
Local Institution
St. Jerome, Quebec, Canada
Local Institution
Belfort, France
Local Institution
Besancon, France
Local Institution
Poitiers, France
Local Institution
Saint-Herblain Cedex, France
Local Institution
Strasbourg, France
Local Institution
Tours, France
Local Institution
Napoli, Italy
Local Institution
Orbassano Torino, Italy
Local Institution
Perugia, Italy
Local Institution
Roma, Italy
Local Institution
Amsterdam, Netherlands
Local Institution
Maastricht, Netherlands
Local Institution
Barcelona, Spain
Local Institution
Madrid, Spain
United Kingdom
Local Institution
Cambridge, Cambridgeshire, United Kingdom
Local Institution
Glasgow, Central, United Kingdom
Local Institution
Plymouth, Devon, United Kingdom
Local Institution
London, Greater London, United Kingdom
Local Institution
Northwood, Middlesex, United Kingdom
Local Institution
Oxford, Oxfordshire, United Kingdom
Sponsors and Collaborators
Bristol-Myers Squibb
Layout table for additonal information Identifier: NCT00359450    
Other Study ID Numbers: CA165-026
EUDRACT: 2005-005099-33
First Posted: August 2, 2006    Key Record Dates
Last Update Posted: March 2, 2010
Last Verified: September 2007
Keywords provided by Bristol-Myers Squibb:
Locally advanced or metastatic non-small cell lung cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents